Results of treatment of Graves-Basedow disease with 131I at low calculated doses;Resultados del tratamiento de la enfermedad de Graves Basedow con 131I a dosis bajas calculadas

Revista Clinica Espanola

Volumn 198, Issue 2, 1998, Pages 57-60

  Gomez Arnaiz N ^a,b   Gomez Saez J M ^a   Orti Llaveria A ^a   Gavalda Mestre L ^a   Mairal Pairo L ^a   Soler Ramon J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b NONE   (Spain)

Author keywords

131I therapy; Graves' disease; Hypothyroidism; Relapse

Indexed keywords

IODINE 131;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0141619667     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Romaldini JH. Bromberg N. Wernwe RS Compansion of effects of high and low dosage regimenes of antithyroid in the management of Graue s hyperthyroidism J Clin Endocrinol Metab 1983: 57:563-570.
2. Allanic H, Fauchet R, Orgiazzi J. Antithyroid drugs and Grave's disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70:675-679.
3. Winsa B, Dahlberg PA, Jansson R, Agren H, Karisson FA Factors influencing the outcome of thyrosiatic drug therapy in Grave's disease. Acta Endocrinol (Copenh) 1990; 122: 722-728.
4. DeGroot LJ, Larsen PR, Refetoff S, Stanbury JB. The thyroid and its diseases New York. Wiley & Sons. 1984; 438.
5. Farnell MB, Van Heerden JA, McConahey WM. Hypothyroidism after thyroidectomy for Graves' disease Am J Surg 1981; 142:535-538.
6. Michie W, Peg CAS, Bewsher PD. Prediction of hypothyroidtsm after partial thyroidectomy for thyrotoxicosis Br Med J 1972; 1:13-17
7. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Grave's disease in Europe in 1986. Acta Endocrinol (Copenh) 1987, 285.4-23.
8. Solomon B, Glinoer D, Lagasse R, Wartofsky L Current trends in the management of Grave's disease. J Clin Endocrinol Metab 1990: 70:1.518-1.524.
9. Dobyns BM. Sheline GE. Workman JB, Tompkings EA, McConahey W. Becker DV. Malignant and benign neoplasm of the thyroid in patients treated for hyperthyroidism; a report of the co-operative thyrotoxicosis therapy follow-up study J Clin Endocrinol Metab 1974; 38:976-998.
10. '31I) for hyperthyroidism N Engl J Med 1975; 292:167-171.
11. Enksson E, Ericksson K, Wahlberg P Treatment of hyperthyroidism with standard doses of radioiodine aiming at ablation. Acta Med Scand 1985; 217:55-60.
12. Kendall-Taylor P, Keir MJ, Ross WM Ablative radioiodine therapy for hyperthyroidism Long-term follow-up study Br Med J 1984; 289:361-363
13. Ratcliffe GE, Fogelman I, Maisey MN. The evaluation of radioiodine therapy for thyroid patients using a fixed dose regime. Br J Radiol 1986, 59.1 105-1 107.
14. Nordyke RA, Gilbert FI, Optimal iodine-131 dose for eliminating hyperthyroidism in Grave's disease. J Nucl Med 1991, 32.487-496
15. 131I therapy for Grave's disease Clin Endoerinol (Oxf) 1988, 23.487-496
16. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991, 34:71-76.
17. Goolden AWG. Stewart JSW Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1986. 24 217-222.
18. Holm L, Israelsson A, Dahlquist I Incidence of hypothyroidsm long after iodine 131 therapy for hyperthyroidism. J Nucl Med 1986, 23:103-107.
19. 131I therapy for Grave's disease N Engl J Med 1984, 16:426-432.
20. Dunn J, Medeiros-Neto G. Endemic goitre and creatinism: continuing threats to world. Washington D C. Pan American Health Organization. Who 1974; 292-1-195.
21. Irvine WJ, Toft AD, Lidgard GP, Gray RS, Seth J. Cameron EHD. Spectrum of thyroid function in patients remaining in remission after anuthyroid drug therapy for thyrotoxicosis. Lancet 1977; ii:179-181.
22. Gómez N, Gómez JM, Orti A. Gavaldà L, Villabona C, Leyes P, Soler J. Transient hypothyroidism after iodine-131 therapy for Grave's disease. J Nucl Med 1995; 36:1.539-1.542.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53.457-481.
24. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
25. 131I Prevalencia del hipotiroidismo transitono. Rev Clin Esp 1988; 183:300-303.
26. Vestergaard H, Laurberg P. Radioiodine treatment of recurrent hyperthyroidism in patients previously treated for Grave's disease by subtotal thyroidectomy. J Intern Med 1992; 231.13-17.
27. Cornell JM, Hilditch TE, Robertson J, Coghill G, Alexander WD. Radioprotecuve action of carbimazole in radioiodine therapy for thyrotoxicosis. Eur J Nucl Med 1987; 13:358-361.
28. Althaus B. Staub JJ. Neri TM. et al. HLA DR3 and DRw6 prognostic factors for the incidence of hypothyroidism in Grave's disease after radioiodine treatment Acta Endocrinoi (Cophen) 1986; 113-323-328.
29. Velkerniers B, Vanhaeist L Cytryn R, Jonckheer MH. Treatment of hyperthyroidism with radioiodine. adjuntive therapy with antithyroid drugs reconsidered. Lancet 1988; 21.1.127-1 129.
30. Marcocci C, Gianchecchi D, Masini I, A reppraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Grave's hyperthyroidism J Endocrinoi Invest 1990; 13:513-520,
31. 131I) therapy for hyperthyroid Grave's disease. Endoerinol Jpn 1991, 38.429-433.